<DOC>
	<DOC>NCT00358956</DOC>
	<brief_summary>This will be a Phase II, open label study to establish the effect of once-daily oral doses of ZD6474 100mg in subjects with locally advanced or metastatic hereditary medullary thyroid cancer in whom no standard therapeutic option is available.</brief_summary>
	<brief_title>A Study To Assess ZD6474 (ZACTIMAâ„¢) Monotherapy In Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer</brief_title>
	<detailed_description />
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Neuroendocrine</mesh_term>
	<criteria>Provision of written informed consent Previously confirmed histological diagnosis of locally advanced or metastatic hereditary medullary thyroid carcinoma without standard therapeutic options Aged 18 or over and a life expectancy of more than 12 weeks The last dose of prior chemo/radiation received less than 4 weeks before the start of study therapy Congenital long QT syndrome or 1st degree relative with unexplained sudden death under 40 years of age, history of arrhythmia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>medullary thyroid cancer</keyword>
	<keyword>MTC</keyword>
	<keyword>hereditary medullary thyroid cancer</keyword>
	<keyword>thyroid cancer</keyword>
</DOC>